Skip to content. | Skip to navigation

University of Piemonte Orientale

Personal tools

You are here: Home / Teachers / Roberta ROLLA / Roberta ROLLA: List of publications


Roberta ROLLA: List of publications

  1. Rolla R, Vidali M, Sartori M, Andorno S, Pagliarulo M, Carmagnola S, Ballaré M, Orsello M, Montino F, Anderloni A, Suno A, Del Piano M, Bellomo G. Does Asymmetric Dimethylarginine (Adma) Plasma Concentration Predict Esophageal Varices in Patients with Cirrhosis? Epub ahead of print
  2. Rolla R, Gramaglia C, Dalò V, Ressico F, Prosperini P, Vidali M, Silvia Meola S, Paola Pollarolo P, Bellomo G, Torre E, Zeppegno P. An Observational Study of Venlafaxine and CYP2D6 in Clinical Practice. Clin. Lab. 2014;60:225-231.
  3. Rolla R, Bellomo G. Combined and Sequential Use of Activated Protein C Resistance and Molecular Genetic Test for the Diagnosis of Factor VLeiden: A New Laboratory Approach. Clin Lab. 2013;59:1187-8.
  4. Verdoia M, Pergolini P, Camaro C, Restifo M, Rolla R, Schaffer A, Di Giovine G, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Blood Coagul Fibrinolysis. 2013;24:411-8.
  5. Rolla R, Vidali M, Meola S, Pollarolo P, Fanello MR, Nicolotti C, Saggia C, Forti L, Agostino FD, Rossi V, Borra G, Stratica F, Alabiso O, Bellomo G. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen. Clin Lab. 2012;58:1211-8.
  6. Vidali M*, Rolla R*, Parrella M, Cassani C, Manzini M, Portalupi MR, Serino R, Prando MD, Bellomo G, Pergolini P (*These authors equally contributed to the work).  Role of the laboratory in monitoring patients receiving dual antiplatelet therapy. Int J Lab Hematol. 2012;34:484-94.
  7. Bellomo G, Sulas MG, Mairate E, Bardone MB, Rolla R. Hemolysis is a major cause of variability in insulin measurement during oral glucose tolerance test in children. Clin Lab. 2012;58:67-74.
  8. Lupi A, Secco GG, Rognoni A, Rossi L, Lazzero M, Nardi F, Rolla R, Bellomo G, Bongo AS, Di Mario C. Plasma fibrinogen levels and restenosis after primary percutaneous coronary intervention. J Thromb Thrombolysis. 2012;33:308-17.
  9. Rolla R, Vidali M, Meola S, Pollarolo P, Pergolini P, Bellomo G. Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden. Clin Lab. 2011;57:711-7.
  10. Zeppegno P, Rolla R, Dalò V, Ressico F, Parafioriti A, Prosperini P., Vidali M, Bellomo G, Torre E (2011). Venlafaxine and CYP2D6 in clinical practice: a case report. IMAGO 2011, vol. 17, p. 450-452, ISSN: 1124-3031
  11. Rolla R, Vidali M, Serino R, Pergolini P, Albano E, Bellomo G. Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity. Clin Exp Immunol. 2007; 149:63-9.
  12. Sartori M, Andorno S, Pagliarulo M, Rigamonti C, Bozzola C, Pergolini P, Rolla R, Suno A, Boldorini R, Bellomo G, Albano E. Heterozygous beta-globin gene mutations as a risk factor for iron accumulation and liver fibrosis in chronic hepatitis C. Gut. 2007; 56:693-8.
  13. Vidali M, Hidestrand M, Eliasson E, Mottaran E, Reale E, Rolla R, Occhino G, Albano E, Ingelman-Sundberg M. Use of molecular simulation for mapping conformational CYP2E1 epitopes. J Biol Chem. 2004; 279:50949-55.
  14. Rigamonti C, Mottaran E, Reale E, Rolla R, Cipriani V, Capelli F, Boldorini R, Vidali M, Sartori M, Albano E. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 2003; 38:42-9.
  15. Vidali M, Stewart SF, Rolla R, Daly AK, Chen Y, Mottaran E, Jones DE, Leathart JB, Day CP, Albano E. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Hepatology 2003; 37:410-9.
  16. Stewart SF, Leathart JB, Chen Y, Daly AK, Rolla R, Vay D, Mottaran E, Vidali M, Albano E, Day CP. Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. Hepatology 2002; 36:1355-60.
  17. Mottaran E, Stewart SF, Rolla R, Vay D, Cipriani V, Moretti M, Vidali M, Sartori M, Rigamonti C, Day CP, Albano E. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radic Biol Med. 2002; 32:38-45.
  18. Rolla R, Vay D, Mottaran E, Parodi M, Vidali M, Sartori M, Rigamonti C, Bellomo G, Albano E. Antiphospholipid antibodies associated with alcoholic liver disease specifically recognise oxidised phospholipids. Gut. 2001; 49:852-9.
  19. Vay D, Parodi M, Rolla R, Mottaran E, Vidali M, Bellomo G, Albano E. Circulating antibodies recognizing malondialdehyde-modified proteins in healthy subjects. Free Radic Biol Med. 2001; 30:277-86.
  20. Vay D, Vidali M, Allochis G, Cusaro C, Rolla R, Mottaran E, Bellomo G, Albano E. Antibodies against advanced glycation end product Nepsilon-(carboxymethyl) lysine in healthy controls and diabetic patients. Diabetologia. 2000;43:1385-8.
  21. Rolla R, Vay D, Mottaran E, Parodi M, Traverso N, Aricó S, Sartori M, Bellomo G, Klassen LW, Thiele GM, Tuma DJ, Albano E. Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease. Hepatology 2000; 31:878-84.
This is Schools Diazo Plone Theme